EGFR and non-small cell lung carcinoma: Another phase II trial, LUNG-MAP (NCT05642572), opened, investigating capmatinib with osimertinib with or without ramucirumab in EGFR-mutant, MET-amplified stage IV or recurrent NSCLC.